117 related articles for article (PubMed ID: 28570737)
1. Subconjunctival Delivery of p75NTR Antagonists Reduces the Inflammatory, Vascular, and Neurodegenerative Pathologies of Diabetic Retinopathy.
Galan A; Barcelona PF; Nedev H; Sarunic MV; Jian Y; Saragovi HU
Invest Ophthalmol Vis Sci; 2017 Jun; 58(7):2852-2862. PubMed ID: 28570737
[TBL] [Abstract][Full Text] [Related]
2. The route of administration influences the therapeutic index of an anti-proNGF neutralizing mAb for experimental treatment of Diabetic Retinopathy.
Barcelona PF; Galan A; Nedev H; Jian Y; Sarunic MV; Saragovi HU
PLoS One; 2018; 13(6):e0199079. PubMed ID: 29927948
[TBL] [Abstract][Full Text] [Related]
3. A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema.
Dugel PU; Blumenkranz MS; Haller JA; Williams GA; Solley WA; Kleinman DM; Naor J
Ophthalmology; 2012 Jan; 119(1):124-31. PubMed ID: 22115710
[TBL] [Abstract][Full Text] [Related]
4. Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial.
Lim JW; Lee HK; Shin MC
Ophthalmologica; 2012; 227(2):100-6. PubMed ID: 21997197
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial.
Riazi-Esfahani M; Riazi-Esfahani H; Ahmadraji A; Karkhaneh R; Mahmoudi A; Roohipoor R; Ghasemi F; Yaseri M
Int Ophthalmol; 2018 Apr; 38(2):585-598. PubMed ID: 28349504
[TBL] [Abstract][Full Text] [Related]
6. Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema.
Ozdek S; Bahçeci UA; Gürelik G; Hasanreisoğlu B
J Diabetes Complications; 2006; 20(4):246-51. PubMed ID: 16798476
[TBL] [Abstract][Full Text] [Related]
7. The duration of effect of centrifuge concentrated intravitreal triamcinolone acetonide.
Ober MD; Valijan S
Retina; 2013 Apr; 33(4):867-72. PubMed ID: 23528704
[TBL] [Abstract][Full Text] [Related]
8. p75NTR and Its Ligand ProNGF Activate Paracrine Mechanisms Etiological to the Vascular, Inflammatory, and Neurodegenerative Pathologies of Diabetic Retinopathy.
Barcelona PF; Sitaras N; Galan A; Esquiva G; Jmaeff S; Jian Y; Sarunic MV; Cuenca N; Sapieha P; Saragovi HU
J Neurosci; 2016 Aug; 36(34):8826-41. PubMed ID: 27559166
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
[TBL] [Abstract][Full Text] [Related]
10. Diabetic macular edema before and after intravitreal triamcinolone injection.
Ramezani A; Tabatabaie H; Ahmadieh H
Korean J Ophthalmol; 2007 Jun; 21(2):95-9. PubMed ID: 17592240
[TBL] [Abstract][Full Text] [Related]
11. [Complications of intravitreal injections--own experience].
Jamrozy-Witkowska A; Kowalska K; Jankowska-Lech I; Terelak-Borys B; Nowosielska A; Grabska-Liberek I
Klin Oczna; 2011; 113(4-6):127-31. PubMed ID: 21913440
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of intravitreal triamcinolone acetonide injection in macular edema associated with retinal vascular disorders.
Tewari HK; Sony P; Chawla R; Garg SP; Venkatesh P
Eur J Ophthalmol; 2005; 15(5):619-26. PubMed ID: 16167293
[TBL] [Abstract][Full Text] [Related]
13. Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema.
Jonas JB; Spandau UH; Kamppeter BA; Vossmerbaeumer U; Harder B; Sauder G
Ophthalmology; 2006 May; 113(5):800-4. PubMed ID: 16530840
[TBL] [Abstract][Full Text] [Related]
14. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.
Cardillo JA; Melo LA; Costa RA; Skaf M; Belfort R; Souza-Filho AA; Farah ME; Kuppermann BD
Ophthalmology; 2005 Sep; 112(9):1557-63. PubMed ID: 16019075
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of intravitreal bevacizumab with or without triamcinolone acetonide for treatment of diabetic macular edema.
Jin E; Luo L; Bai Y; Zhao M
Ann Pharmacother; 2015 Apr; 49(4):387-97. PubMed ID: 25622852
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal injection of adenosine A
Aires ID; Madeira MH; Boia R; Rodrigues-Neves AC; Martins JM; Ambrósio AF; Santiago AR
Sci Rep; 2019 Nov; 9(1):17207. PubMed ID: 31748653
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal injection of triamcinolone for diffuse diabetic macular edema.
Chan CK; Chan WM; Cheung BT; Yuen CY; Lee VY; Lam DS
Arch Ophthalmol; 2004 Jul; 122(7):1083-5; author reply 1086-8. PubMed ID: 15249387
[No Abstract] [Full Text] [Related]
19. Comparison of topical and subconjunctival anesthesia in intravitreal injection administrations.
Kaderli B; Avci R
Eur J Ophthalmol; 2006; 16(5):718-21. PubMed ID: 17061223
[TBL] [Abstract][Full Text] [Related]
20. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema.
Soheilian M; Garfami KH; Ramezani A; Yaseri M; Peyman GA
Retina; 2012 Feb; 32(2):314-21. PubMed ID: 22234244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
